Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

BACKGROUND: To date, there are no effective therapeutic targeting agents for triple-negative breast cancer (TNBC), and PD-L1 has presented potential as an effective marker of immunotherapeutic agents. The aim of this study was to evaluate the expression of PD-L1 by three different immunohistochemica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Woo Young, Lee, Yu Kyung, Koo, Ja Seung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902914/
https://www.ncbi.nlm.nih.gov/pubmed/27286842
http://dx.doi.org/10.1186/s12967-016-0925-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902914/
https://www.ncbi.nlm.nih.gov/pubmed/27286842
http://dx.doi.org/10.1186/s12967-016-0925-6

Ejemplares similares